Union health ministry approves new treatment for multi-drug resistant TB
The Union Health Ministry has approved the BPaLM regimen for multi-drug resistant tuberculosis (MDR-TB), combining Pretomanid, Bedaquiline, Linezolid, and Moxifloxacin. This new, effective, and shorter six-month treatment offers a significant improvement over traditional methods, aligning with India's goal to eliminate TB by 2025.
The Union Health Ministry has approved the introduction of the BPaLM regimen, a novel treatment for multi-drug resistant tuberculosis (MDR-TB) under its National TB Elimination Program (NTEP) as a highly effective and shorter treatment option. This regimen includes a new anti-TB drug namely Pretomanid in combination with Bedaquiline and Linezolid (with or without Moxifloxacin), the ministry said in a statement.\ Pretomanid has earlier been approved and licensed for use in India by the Central Drugs Standard Control Organization (CDSCO).
The BPaLM regimen, which consists four-drug combination -- Bedaquiline, Pretomanid, Linezolid and Moxifloxacin -- has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure, the ministry said."While traditional MDR-TB treatments can last up to 20 months with severe side effects, BPaLM regimen can cure the drug-resistant TB in just six months with a high treatment success rate," the statement read."India's 75,000 drug-resistant TB patients will now be able to avail the benefit of this shorter regimen," the ministry said.
The Department of Health and Family Welfare, in consultation with the Department of Health Research ensured the validation of this new TB treatment regimen that witnessed a thorough review of evidence by in-country subject experts. It also got a Health Technology Assessment done through the Department of Health Research to ensure that this MDR-TB treatment option is safe and cost-effective, the statement said. This move by the government is expected to significantly boost the country's progress to achieve its national goal of ending TB.
A country-wide time-bound rollout plan of the BPaLM regimen is being prepared by the Central TB Division of the Ministry of Health and Family Welfare in consultation with the states and UTs. It includes rigorous capacity building of health professionals for the safe administration of the new regimen. Under the vision of Prime Minister Narendra Modi, India has set a target to get rid of TB by 2025, five years ahead of the global target for eliminating the disease under the Sustainable Development Goals.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
06:30 PM IST